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Practice points
 Amyotrophic lateral sclerosis patients are supported by models of patient-centered decision making delivered
through specialized multidisciplinary clinics.
 Advances in research have led to changes in service delivery, with new members added to the multidisciplinary
team.
 Developments in genetics research have increased the complexity of patients’ choices for genetic testing.
 User-designed decision support tools could improve communication between patients’ families and clinicians, to
negotiate this complex and ever-changing care.
Developmentsin amyotrophic lateral sclerosis research and care delivery have created new arenas, and
new dilemmas, for patients’ decision making. This review explores three aspects of amyotrophic lateral
sclerosis patient-centered care and decision making: patient-centered service delivery through the ex-
panding multidisciplinary team; decision making for genetic testing and the implications of undergoing
testing; and development of user-designed decision support tools to help patients and families make de-
cisions as their choices become more complex. Until a cure is found, well-timed and effective decision
making will rely on patient and family preferences to guide them through an increasingly complicated
disease landscape.
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Amyotrophic lateral sclerosis (ALS) is a disease in search of a cure, or at least a highly effective treatment that will
alleviate symptoms and slow disease progression. Until this can be achieved, people living with ALS, and their
families, rely on healthcare services to help them manage their symptoms and maximize their quality of life as their
needs increase. Best practice for people with ALS adopts a multidisciplinary approach of specialized care [1] that
draws on patient- (or person-) centered principles and practices for cohesive and collaborative care [2].
Patient-centered care, and the decision making that underpins it, have been defined, conceptualized and modeled
many times [3–7]. In short, four principles [5] apply: affording people dignity, respect and compassion; offering
coordinated care; offering personalized care; and enabling people to develop their unique range of capabilities to
participate in their own care. Shared decision making, where patients and health professionals collaborate to arrive
at a care decision, is considered best practice for patient-centered healthcare delivery [8]. Although preferences for
sharing decision making vary with age, cultural background and disease setting [9–11], a majority of patients prefer
to make their decisions using this approach [9]. Decision making for ALS care is often more complicated than
for other degenerative conditions, as continual change in the patient’s condition and circumstances mean that
decision making is ongoing throughout the, frequently brief, course of the disease. Time frames for choosing and
implementing a treatment may be short; and the number of health professionals to consult may be extensive; with
multiple decisions under consideration at one time.
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Table 1. Multidisciplinary team support for patient decision making.
Issue Treatment options Healthcare and support professionals involved
Familial ALS Genetic testing Neurologist, genetic counselor
Disease progression Riluzole Neurologist/rehabilitation physician
Breathing difficulty Assisted ventilation – Respiratory physician
– Respiratory therapist
– Nursing
Eating and drinking difficulties Gastrostomy – Gastroenterologist
– Dietitian
– Speech pathologist
– Nursing
Safe swallowing strategies Speech pathologist
Saliva management Medication Neurologist/general practitioner/palliative care team
Botox Neurologist
Natural remedies and swallowing behavior Speech pathologist
Mobility Mobility equipment – Physiotherapist
– Occupational therapist
– ALS association
Cognitive and behavior change Assessment and support for patient and family
Guidance for team
– Neuropsychologist
– Psychologist
Self-care Assistive equipment and strategies – Occupational therapist
– Nursing
– ALS association
Assistance with personal care Purchased care services – Social worker
– Occupational therapist
Communication Alternative communication strategies and devices – Speech pathologist
– Occupational therapist
– ALS association
Grief and loss Counseling and support for patient and family – Social worker
– Psychologist
– ALS association
– Palliative care team
Family carer support Counseling and support for patient and family – Social worker
– ALS association
– Palliative care team
Information provision Access to health literature and research – ALS association
– MDC team
ALS: Amyotrophic lateral sclerosis; MDC: Multidisciplinary clinic.
How people with ALS patients respond to these complexities varies [12]. A small proportion of patients choose
to make decisions independently of professional advice, or independently of family considerations [13]. Some prefer
to share their decision making only with family members. Others rely on health professionals or family members
to make decisions for them [13]. Studies reveal that, in many degenerative conditions, patient preferences for
involvement of others can vary over time [14], or with each decision, but it is unknown if this is the same for people
with ALS.
This review explores what is known about ALS patient decision making; that is, how patient-centered principles,
and the clinical processes and activities by which they are enacted [5], are implemented within ALS service delivery.
Three aspects of ALS care are discussed, to reveal how research developments have translated into patient care,
and influenced decision making. These processes and activities are: the multidisciplinary model of service delivery,
decision making for genetic testing and user-designed decision support tools for patients.
Patient-centered service delivery
Multidisciplinary clinic (MDC) teams specializing in ALS provide best possible care for, and improve survival
of, people living with ALS [15–17]. The teams are comprised of a range of medical, nursing and allied health
practitioners, taking an integrated approach to address patients’ symptom management, psychosocial and quality
of life needs [18–20] (Table 1).
MDC care for ALS is underpinned by evidence from healthcare research [13,21], and supported by clinical
standards and guidelines [1,22–25] that reinforce the importance of meeting patients at their current and projected
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points of need, rather than merely addressing a set of deteriorating symptoms. Not all patients are able to attend an
MDC; but, despite numerous barriers to attendance [26], the proportion of patients who have been able to access
specialized multidisciplinary services is high internationally [20].
Since their establishment in the late 1990s [27],MDCs have evolved to accommodate new treatments and practices
that have emerged from research findings. Remote services using telehealth are emerging [28]. Teammembership has
expanded to provide more comprehensive care as understanding of the disease improves. Of note, the association
between frontotemporal dementia (FTD) and ALS [29], and development of mild cognitive and behavioral change
in many ALS patients [30], has seen neuropsychologists added to the MDC team. Neuropsychologists provide
assessment and advice to patients and family members, and guidance to the MDC team, particularly where
concerns are held about the patient’s capacity for making informed decisions. Similarly, advances in ALS gene
identification have led to genetic counselors working more closely with ALS patients and family members [31].
Their role is discussed in greater detail below.
Patient-centered care and decision making have long been fundamental to models of MDC care [15,19,32–33],
but our notion of who forms this ‘patient center’ has changed over time. While family members providing care
are included in many models of ALS MDC care [18–19,25], it is not until recently that the extent and value of that
care have been documented. As family caregivers often shoulder the physical, emotional, logistical and financial
burden of care, including economic disadvantage through loss of productivity [34,35], many are placed in the role
of co-decision maker alongside the patient. For some, the role is of proxy decision maker, if the patient’s capacity
for decision making becomes impaired by FTD. In these circumstances, patient-centeredness is characterized by
negotiation between what the patient wants, and what is considered to be in their best interest. Thus, for many
families, patient-centered care includes addressing the needs of the patient’s caregiver [36,37], to allow them to
continue this support. Addressing carers’ needs from within, and in addition to MDC care [36,38], has potential to
reduce the strain associated with caregiving [38].
How well MDCs and general health services respond to the growing role and support needs of caregivers is yet to
be seen. People with ALS, and their carers, who are unable to access MDCs are faced with the additional challenge
of how best to receive care from services where ALS is not a high-priority caseload, or where practitioners have
little experience of the disease. Tools such as the Red Flags checklist [39] that support the general practitioner (GP)
– or family physician – decision making and reduce their uncertainty have potential to improve practitioners’
awareness of the needs of ALS patients. Furthermore, service delivery that is guided by patient preferences becomes
key to negotiating care when treatment and service options are of limited effect and availability. Care delivered
by practitioners working in isolation can be patient centered within each clinical encounter, supported by shared
decision making. However, patient-centered care is more difficult to maintain along the chain of service provision
between unconnected, internal and external service providers, without an agreed care model to underpin it.
Decision making for genetic testing
Interest in finding a cure or treatments that reduce symptoms or enable a normal lifespan, and the desire to help
future generations, has encouraged patients and their family members to participate in ALS research [40]. 10%
of ALS cases are estimated to be familial, and to date, more than 20 genes have been discovered that are causal
or associated with ALS, along with other conditions, such as FTD [41]. Only two-thirds of clearly familial cases
have a known causal gene mutation, and therefore further gene discovery is likely [42–44]. Even a small proportion
of individuals with apparently sporadic ALS have been identified to carry a causative gene mutation [44,45], and
therefore the number of cases thought to be familial may be an underestimate [46].
Over the past 25 years, our growing understanding of inherited ALS has provided more opportunities for patients
to undergo diagnostic genetic testing to determine whether they carry a causal mutation in an ALS gene (Figure 1).
Once a causal gene mutation is identified in an individual, there is currently no change to the patient’s medical
care or management, although drug therapy trials may be targeted to certain gene mutation carriers in future [47,48].
Their unaffected relatives can undergo predictive genetic testing to determine whether they have inherited the
mutation, and are at risk of developing the disease in future. Genetic testing and counseling practice for ALS
genes differs in research and clinic settings, and between countries and clinicians [49]. Genetic counseling is a
general requirement for individuals undergoing predictive genetic testing, and is based on shared decision making
principles [50]. In this process, the various medical, psychological, social, familial and reproductive factors that
influence and impact pretest decision making are raised, with the aim to help individuals make an informed
decision about genetic testing, and at the same time minimize adverse outcomes, such as emotional, ethical and
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Figure 1. Process of clinical genetic testing for amyotrophic lateral sclerosis genes.
NB: Not all genetic testing options are accessible everywhere.
†Individuals who do not wish to know their mutation status can also consider options to prevent passing on the mutation, such as
grandparental exclusion studies via PND or PGD, or nondisclosure through PGD.
FTD: Frontotemporal dementia; PGD: Preimplantation genetic diagnosis; PND: Prenatal diagnosis.
legal implications [23,51–52]. Multiple family members (including carers and blood relatives) may be involved in the
shared decision making about genetic testing, given:
 the results of testing may have medical, emotional, social and (potential) insurance implications on not only the
patient being tested, but also their family members [51];
 the ALS patient may also have FTD or some cognitive impairment and therefore they may not be cognizant of
informed consent, and require another person as proxy decision maker.
Crook et al. (2017) recently reviewed research assessing why individuals choose to have predictive genetic testing
for familial ALS and/or FTD genes, to reveal a variety of reasons [53]. These include hope for a 50% chance of
testing negative for the family mutation [54,55]; alleviation of anxiety; and freedom from uncertainty [54,55]. The
information individuals gain may help them to alter life priorities, such as family, financial, lifestyle, goal and
relationship planning [54,56]; enable time to be psychologically prepared for the future; and be proactive about their
health. Still, the uptake of genetic counseling and predictive genetic testing in individuals at risk of inheriting an
ALS gene mutation is estimated to be less than 10% [56,57].
Reasons for declining testing are similarly varied, and sensitive to individual’s preferences and values. There are
no preventative measures currently available to prevent, delay or effectively slow disease progression to allow a
normal lifespan [55]. Moreover, for people who test positive, there are potentially negative consequences for their
future employment, insurance, personal and family relationships, privacy, confidentiality and opportunities for
their family [55]. Family member’s concerns about coping with disclosure of results may result in increased anxiety,
depression and stress; feelings of loss of control; feeling flawed; anger and frustration; and worry about developing
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disease [55]. Additionally, some may wish to avoid guilt related to passing on gene, inheriting or even not inheriting
the family mutation (a form of ‘survivor guilt’) [55]. Residual uncertainty relating to if, when and how the condition
will manifest will remain. Other reasons to reject testing include: guilt over tampering with nature [55]; an individual
believing they already have the gene mutation and thinking continually about the disease [54]; feeling at risk of
unresolved grief for a loved one lost to ALS/FTD; and evoking traumatic childhood memories of the disease [54].
Patient and family decisions become even more complex when family planning is considered. Individuals in
familial ALS families with known gene mutations also have opportunity to consider reproductive options to prevent
passing on the causal gene mutation to their future children. If taken up, these methods can also prevent and reduce
the overall incidence of ALS in the next generation.
Studies assessing reproductive decisionmaking in familial ALS have revealed a range of responses to this option [55–
56,58]. These include: doing nothing differently (retaining a 50% chance for each pregnancy that the mutation has
been passed on); choosing not to have children; prenatal diagnosis; pre-implantation genetic diagnosis (via in
vitro fertilization); and conception using donor sperm or egg via in vitro fertilization. Even so, little is understood
about how individuals from these families decide whether to have genetic counseling, have genetic testing and
undergo reproductive options, and the factors that influence decision making and uptake of these options are
largely unknown [54–58].
Evidence-based clinical guidelines to support patient-centered decision making for genetic testing are notable by
their absence.Genetic counseling and genetic testing has been excluded from recent ALSmanagement guidelines [22].
Previous guidelines on genetic testing have not kept pace with research developments, with information related to
the SOD1 gene only [23] or lacking reference to the reproductive options available to ALS families [31]. As there
have been few studies on genetic counseling and genetic testing in familial ALS, most existing guidelines draw on
research performed in Huntington’s disease genetic testing [23,31,59–61]. While the diseases have some similarities
in terms of management and carer involvement, additional issues can arise in predictive testing for familial ALS,
as mutations in ALS genes have greater genetic and clinical heterogeneity with variable penetrance, age of onset,
phenotype and prognosis [31,42,56,62–63]. Given this variability, it is possible that individuals from ALS families may
respond to genetic information differently to individuals from Huntington’s disease families [64] and therefore will
require a different set of guidelines for genetic counseling and testing. This highlights an opportunity to develop
more up to date, current guidelines on genetic testing and counseling for ALS genes to assist patients, families and
health professionals to promote patient-centered decision making.
User-designed decision support tools
In addition to choices for genetic testing, people living with ALS face a range of decisions about their care that
can affect their quality of life. As well as evidence-informed practice, there is an increasing demand for information
about experimental, complementary, alternative and off-label treatments with unknown or unclear benefits to
people with ALS. A range of online resources are available to patients and families to make informed choices about
established or emerging treatments. These include ALS support association websites, information sites tapping in
to social media, such as ALSUntangled [65] and peer research forums, such as PatientsLikeMe [66]. Nevertheless, the
course of ALS, and the response of patients and families to receiving this diagnosis, continues to challenge well-
timed and effective decision making [13]. As well as credible sources of information, patients managing deteriorating
neurological symptoms need services that provide timely, skilled care in response to patients’ dynamic priorities and
needs. The uncertainty that accompanies continually changing neurological conditions [67] often renders simple
models of decision making inadequate [13].
One way to support ALS patients and families to make choices in a timely way is through the use of patient-
centered decision making support tools [68]. Decision support tools help patients to make informed and well-timed
choices about treatment, in line with their personal preferences and values [8]. The tools can be used to inform
patients about the treatment options available and the associated risks and benefits of the treatment, including
the likely health and quality-of-life consequences for them in the short- and long-term. Research on effectiveness
indicates that decision support tools can increase patient engagement in healthcare decision making, strengthen
communication between patients and health professionals, reduce unnecessary treatment and avoid emergency
admissions [69].
Decision support tools designed for ALS, and processes for their use in MDC care, can offer a framework to
enhance patient-centered service and quality of care, by guiding care discussions between health professionals,
patients and families. Patients are then equipped to make decisions based on a clear understanding of the risks and
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benefits of the available options, and the possible consequences of delaying active treatment, or choosing to do
nothing [70]. With limited life-extending options available to ALS patients, treatment and care choices based on
patients’ personal preferences and values become increasingly salient to how care is negotiated [71]. Decision support
tools can also help patients to recognize and clarify their personal preferences, values and attitudes that relate to
each decision. This is particularly important in ALS care, where ethically complex and challenging decisions, such
as prolonging life through artificial means, are heavily preference sensitive and value based. Moreover, as current
ALS treatments will not cure, delay or mitigate the disease process, patients can only consider options that alleviate
symptoms, maintain their quality of life, or reduce the risk of a distressing death.
The patient-centered foundation of decision making in ALS is further enhanced by the way decision tools are
designed and developed. To ensure usability by patients and families, and feasibility for clinical care, tools that are
co-designed by patients, carers, health professionals and researchers can be tailored to ALS patients’ specific needs,
with potential to optimize patient and carer participation in care planning, and enhance patient’s quality of life [72].
Tools can facilitate well-timed decisions by providing patients with a greater sense of autonomy and ownership over
planned treatments. The views of health professionals are also important to the tool development process. Their
contribution promotes feasibility of the tools for use in clinical settings, with a focus on placing the patient and
their carers at the core of decision making. Being able to co-design solutions – whether strategies for symptom
management, methods of service delivery, or issues of healthcare policy development – is an effective and rewarding
way of improving the lives of people living with ALS, with the potential of longer-term, sustainable positive impact
on quality of life for both patient and carer [71,73].
Hogden et al. (2016) applied a process of co-design to the development of ALS decision support tools, using
an expert panel of ALS patients, carers, health professionals and researchers, support association representatives
and decision tool researchers [68]. This expert panel identified 56 options for symptom management and quality of
life that are frequently encountered by ALS patients and their families. The options fell into a range of categories
that included medication, procedures, support services, equipment and end-of-life concerns. From these categories,
six high-priority topics were selected as suitable for development into a decision support tool. The topics selected
for development were: use of gastrostomy to support nutrition and hydration; use of assisted ventilation; decision
making for genetic testing; choice of end-of-life care location; choices for communication equipment; and advance
care planning.
Once these tools are developed, two further considerations for patient-centered decision support arise: how will
patients and families access the tools, and how will the tools be delivered in clinical care? The means of access
and delivery are likely to influence the tools’ clinical usefulness and sustainability within clinical practice. Decision
support tools for a range of conditions are available in paper [67], app [74] and web-based [72] formats. While all have
distinct advantages and disadvantages, consideration must be given to what best supports ALS MDC care. Tools
developed as websites are likely to offer greatest benefit, by being easily accessible at both the point of care (clinic
or home based) and outside of clinical consultations by patients and families. Web-based tools can also be readily
updated and maintained as new clinical information becomes available. Thus, they enhance patients’ access to
reliable health literature by linking to websites that offer evidence-based information such as those of ALS support
associations to provide a rich source of best practice information for patients, families and health professionals.
Patients and families can access them from home, in advance of consultations and consequently be better prepared
for decision making. Web-based tools can also be emailed or printed to provide hard copies for patients and families
who prefer to receive paper-based information. Ideally, they can be used in a range of ALS clinical settings, with
individual practitioners or within a multidisciplinary team. Web-based tools accessed from mobile devices, such as
a tablet, laptop or phone, allow clinicians to discuss decision making wherever convenient to the patient.
Future perspective
The worldwide incidence of ALS is projected to increase by 69% by the year 2040 [75]. As research uncovers better
understanding of the causes and treatments of ALS, the need for healthcare services to bridge the gaps between
research and the services routinely offered to ALS patients and families intensifies. Closer integration of ALSMDCs
with ALS research units may be one way to achieve this. Co-location of clinics and research centers, with regional
MDCs connected to a research center as satellites, may facilitate translation of bench findings into direct patient
care, allow closer connection between patients and those attempting to eliminate their disease and offer support to
health professionals and ALS support services. Remote healthcare offered by telehealth may also provide an avenue
for services and researchers to connect with patients and families unable to attendMDCs. Linkage between research
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and healthcare services potentially has a two-way benefit of facilitating high-quality patient care, and promoting
patient participation in consumer-focused research.
Nevertheless, until a cure or highly effective treatment is found, future research findings will serve to make
patients’ symptom management and quality of life choices more complex. Treatment options that are targeted
to ALS phenotypes or to familial ALS genotypes [47–48,76] will necessitate stronger decision making support for
patients and families to understand and consider their options. Patient-centered decision tools and patient-oriented
processes for their use in clinical care will become pivotal to providing support and facilitating communication for
increasingly complex care.
Increasing availability of ALS patient research samples along with whole-genome sequencing technology is likely
to continue to increase our knowledge of the genetic basis of some ALS cases [77]. There is a need for consensus
on who should be offered diagnostic genetic testing for ALS genes, and which genes should be tested. Current
viewpoints range from clearly familial cases only, to all individuals with ALS and FTD [23,31,49]. Yet importantly,
consensus on a definition of familial and sporadic ALS among clinicians is still lacking [49].
As more genes are identified, a process of repeated screening for patients and families is necessitated. Genetic
counseling should be offered routinely to all ALS patients [78], ideally through accessing ALS MDCs. The addition
of genetic counselors to the clinical team enables patients to receive specialized advice in a supportive environment
dedicated to ALS care. Moreover, predictive test counseling could also be conducted through ALS clinics, rather
than patients seeking advice from counselors who have no experience with ALS. In this way, decision making
shared with carers and health professionals remains the cornerstone of effective ALS care. Patient-centered decision
making will continue to be enacted through the processes and activities of specialized MDCs as new discoveries
into the cause and treatment of ALS are made, allowing patient and families to negotiate increasingly complex and
complicated life decisions [79].
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